|
🇪🇺 EMA - Enhanced AMES test conditions
|
|
0
|
573
|
November 15, 2023
|
|
EMA Q&A Rev. 19 (EMA/409815/2020 Rev.19)
|
|
0
|
1421
|
November 13, 2023
|
|
Revised guidance for J-CTN
|
|
3
|
303
|
November 9, 2023
|
|
Nitrosamine Guidance for Cream and Ophthalmic Solutions
|
|
4
|
594
|
November 3, 2023
|
|
🇦🇺 Australia / Nitrosamine impurities in medicines updates
|
|
0
|
621
|
November 2, 2023
|
|
Review of nitrosamine drug substance related impurities (ndsri) in pharmaceutical drugs
|
|
1
|
598
|
October 31, 2023
|
|
🇨🇦 Health Canada Nitrosamine Guide update
|
|
5
|
1660
|
October 27, 2023
|
|
Investigation of experiences in handling N-nitrosamine impurities among ZaZiBoNa participating countries -Pub
|
|
0
|
444
|
October 16, 2023
|
|
🇨🇦 Health Canada extended deadline?
|
|
4
|
548
|
October 23, 2023
|
|
Nitrosamines in food raise a health concern (EFSA)
|
|
5
|
617
|
October 21, 2023
|
|
Reflections on the Impact of Nitrosamine Drug Substance Related Impurities
|
|
0
|
342
|
October 20, 2023
|
|
Vildaglibtin and Metformin in combinationy
|
|
1
|
359
|
October 17, 2023
|
|
CPCA is now included in the updated version of Health Canada’s Guidance on nitrosamine impurities
|
|
15
|
2128
|
October 13, 2023
|
|
🇪🇺 EMA Q&A Rev. 18 EMA/409815/2020 - Deadlines
|
|
2
|
1023
|
October 3, 2023
|
|
🇺🇸 FDA - Recommended Acceptable Intake Limits for NDSRIs Guidance for Industry
|
|
47
|
5801
|
September 20, 2023
|
|
WHO on Nitrosamines, Rifampicin, Rifapentine and NDSRIS
|
|
3
|
797
|
September 20, 2023
|
|
🇪🇺 EMA Q&A Rev. 16 EMA/409815/2020 - MAJOR UPDATE
|
|
108
|
17387
|
September 12, 2023
|
|
Fifth Nitrosamine Implementation Oversight Group (NIOG) – meeting with pharmaceutical industry
|
|
1
|
600
|
September 6, 2023
|
|
🇬🇧 MHRA publishes guidelines for Nitrosamine Impurities
|
|
4
|
1181
|
August 28, 2023
|
|
Q&A revision 17 uploaded on EMA page
|
|
12
|
1333
|
August 25, 2023
|
|
IPA-QF Guidance on Nitrosamines Impurities
|
|
0
|
698
|
August 18, 2023
|
|
Measuring Nitrites in headspace
|
|
4
|
493
|
August 15, 2023
|
|
🇺🇸 FDA Recommended AI Limits for Certain Hypothetical NDSRIs
|
|
0
|
1008
|
August 8, 2023
|
|
Planilha CPCA na prática
|
|
0
|
318
|
August 6, 2023
|
|
The Nitrosamine “Saga”
|
|
3
|
1505
|
July 29, 2023
|
|
NDSRIs: Atualizações e Desafios
|
|
0
|
391
|
July 24, 2023
|
|
Risk Analysis of Colorants and Flavorings in Pharmaceutical Formulations
|
|
9
|
630
|
July 21, 2023
|
|
FDA - Notice on Chantix
|
|
3
|
541
|
July 20, 2023
|
|
Establishment of Acceptable Intakes, framework
|
|
12
|
578
|
July 12, 2023
|
|
New Guidance from Malaysia's NPRA 03 July 2023
|
|
0
|
635
|
July 12, 2023
|